Current Edition


How to Keep Breathing – The Future of Inhaled Medication Testing

The delivery of therapeutics by inhalation is a medical process dating back thousands of years. The first written evidence of this can be found ca. …

Continue Reading →

Former Editas CEO Bosley joins UK venture capital firm

Dive Brief: Katrine Bosley, the former CEO of gene editing biotech company Editas Medicine, has joined U.K.-based Advent Life Sciences as a venture partner, the …

Continue Reading →

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive …

Continue Reading →

ProQR to lay off 30% of staff following eye drug setback

Dive Brief: ProQR Therapeutics is overhauling its research, cutting staff and trying to find a new way forward for its lead drug after a surprising …

Continue Reading →

Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B

Dive Brief: Halozyme Therapeutics, a San Diego-based company whose business revolves around a type of drug delivery technology, announced Wednesday plans to expand its offerings …

Continue Reading →

Akebia to lay off 42% of workforce, suspend trials after FDA drug rejection

Dive Brief: Akebia Therapeutics will lay off 42% of its workforce after the Food and Drug Administration last month rejected its most advanced experimental drug, …

Continue Reading →

Adagio plans comeback for COVID drug, but is it too late?

Dive Brief: Adagio Therapeutics said it will ask the Food and Drug Administration for emergency authorization of its COVID-19 drug after announcing Wednesday that the antibody …

Continue Reading →

‘We have to make a stand’: Biotech leaders vow to break ties with Russia over Ukraine war

Hundreds of biotech leaders are pledging to stop working with Russian companies and to reject investment from Russian funds in response to the country’s invasion …

Continue Reading →

Yumanity cutting 60% of employees as it mulls possible sale

Dive Brief: On the heels of a recent setback, Yumanity Therapeutics, a biotechnology company focused on neuroscience, plans to eliminate about 60% of its workforce …

Continue Reading →

Sage claims new data show depression drug works, but doubts remain

Dive Brief: An experimental, fast-acting depression drug from Sage Therapeutics and partner Biogen met its main goals in a closely watched Phase 3 study that …

Continue Reading →

Star Therapeutics emerges with plans to treat rare diseases through a solar system of drug companies

Few things are as human as gazing into the night sky. And yet, after thousands of years, we know only a little about what we’re …

Continue Reading →

J&J to explore RNA reprogramming with Remix research deal

Dive Brief: Johnson & Johnson is partnering with Remix Therapeutics to develop drugs that are meant to reprogram how RNA is processed, becoming the latest …

Continue Reading →

Innovations in Cell Line Development to Optimise Biotherapeutic Development

Developing stable and high-producing cell lines to manufacture biologics is complex, multi-stage, and time-consuming, often resulting in development timelines that exceed six months when using …

Continue Reading →

NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S

NBE Therapeutics AG, a biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for improved cancer therapy, today announces a CHF 20 million extension of the Series …

Continue Reading →

Orchard Therapeutics Appoints Jim Geraghty as Chairman of its Board of Directors

Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the appointment …

Continue Reading →

Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors

Orchard Therapeutics, a leading commercial stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the …

Continue Reading →

vTv Therapeutics shares soar on licensing tie-up with Chinese group Newsoara Biopharma

Newsoara will develop vTv Therapeutics’ HPP737 as a new treatment for chronic obstructive pulmonary disease vTv Therapeutics (NASDAQ:VTVT) has sold licensing rights to a rival …

Continue Reading →

United Therapeutics nabs competing PAH drug with $216M SteadyMed buy

Brief: United Therapeutics announced Monday morning that it will acquire competitor SteadyMed for $4.46 per share in cash upfront and another $2.63 per share in …

Continue Reading →